Eli Lilly and Company (LLY) SVP Sells $3,152,895.30 in Stock
Eli Lilly and Company (NYSE:LLY) SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.48 during trading hours on Tuesday, hitting $86.06. The stock had a trading volume of 3,876,686 shares, compared to its average volume of 3,672,667. Eli Lilly and Company has a 52 week low of $66.39 and a 52 week high of $89.09. The firm has a market capitalization of $93,945.43, a price-to-earnings ratio of 20.86, a PEG ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the company posted $0.88 earnings per share. analysts predict that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.
Several analysts have weighed in on LLY shares. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their price objective for the stock from $84.23 to $88.00 in a report on Tuesday, October 10th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $90.25.
Institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new stake in Eli Lilly and in the 3rd quarter valued at approximately $916,000. Public Employees Retirement System of Ohio raised its position in Eli Lilly and by 0.4% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 684,533 shares of the company’s stock valued at $58,555,000 after buying an additional 2,452 shares during the last quarter. Garde Capital Inc. acquired a new stake in Eli Lilly and in the 3rd quarter valued at approximately $202,000. Archford Capital Strategies LLC raised its position in Eli Lilly and by 26.2% in the 3rd quarter. Archford Capital Strategies LLC now owns 8,076 shares of the company’s stock valued at $690,000 after buying an additional 1,676 shares during the last quarter. Finally, Salem Investment Counselors Inc. raised its position in Eli Lilly and by 7.5% in the 3rd quarter. Salem Investment Counselors Inc. now owns 48,460 shares of the company’s stock valued at $4,173,000 after buying an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 76.43% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.